Beam Therapeutics Inc. (BEAM) Profit Margins
Over the twelve months to 2026-06-30, Beam Therapeutics Inc. (BEAM) had operating margin -242.3%, net margin -54.7%, free cash flow margin -238.9%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BEAMBeam Therapeutics Inc.Follow BEAM — free
—
Price chart with a free account
- Market cap
- 2.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -553166.7% | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% | -242.3% | |
| Net margin | -810800.0% | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% | -54.7% | |
| FCF margin | -467075.0% | -218.1% | -43.4% | -48.4% | -560.8% | -257.7% | -238.9% |
USD billions · SEC XBRL
Beam Therapeutics Inc. — questions
- What is Beam Therapeutics Inc.'s operating margin?
- -242.3% over the twelve months to 2026-06-30.
- What is Beam Therapeutics Inc.'s net profit margin?
- -54.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Beam Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.